Circ_0030411 aggravates cisplatin-resistance in non-small cell lung cancer by serving as a miR-495-3p sponge to enhance CCND1 expression

References

• Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet. 2021;398(10299):535–554.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA A Cancer J Clinic. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Xiao PP, Luo BQ, Fan W, et al. Simultaneous presentation of multiple myeloma and lung cancer: case report and Gene Bioinfo Anal. Front Oncol. 2022;12:859735.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
   PubMed Web of Science ®Google Scholar
• Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375:n2363.
   PubMedGoogle Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Yano T, Shimokawa M, et al. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. Lung Cancer. 2018;124:255–259.
   PubMed Web of Science ®Google Scholar
• Desage AL, Bouleftour W, Tiffet O, et al. Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature. Transl Lung Cancer Res. 2021;10(12):4643–4665.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5(5):e1257.
   PubMedGoogle Scholar
• Yang Z, Schumaker LM, Egorin MJ, et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006;12(19):5817–5825.
   PubMed Web of Science ®Google Scholar
• Chen P, Li J, Chen YC, et al. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cell Oncol (Dordr). 2016;39(6):511–522.
   PubMed Web of Science ®Google Scholar
• Skowron MA, Oing C, Bremmer F, et al. The developmental origin of cancers defines basic principles of cisplatin resistance. Cancer Lett. 2021;519:199–210.
   PubMed Web of Science ®Google Scholar
• Lu Z, Fang Z, Guo Y, et al. Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA. Chem Biol Interact. 2022;351:109705.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.
   PubMed Web of Science ®Google Scholar
• Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. Embo J. 2019;38(16):e100836.
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453–461.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Jakobsen T, Hager H, et al. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188–206.
   PubMed Web of Science ®Google Scholar
• Yang B, Li L, Tong G, et al. Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/akt axis. J Exp Clin Cancer Res. 2021;40(1):235.
   PubMed Web of Science ®Google Scholar
• Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31–44.
   PubMed Web of Science ®Google Scholar
• Fang L, Lv J, Xuan Z, et al. Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2-mediated autophagy. Clin Transl Med. 2022;12(1):e708.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Z, Zhou X, et al. Circ_0000467 exerts an oncogenic role in colorectal cancer via miR-330-5p-dependent regulation of TYRO3. Biochem Genet. 2022;60(5):1488–1510.
   PubMed Web of Science ®Google Scholar
• Lu H, Xie X, Wang K, et al. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells. Mol Cell Biochem. 2020;475(1-2):63–77.
   PubMed Web of Science ®Google Scholar
• Papatsirou M, Artemaki PI, Scorilas A, et al. The role of circular RNAs in therapy resistance of patients with solid tumors. Per Med. 2020;17(6):469–490.
   PubMedGoogle Scholar
• Bartel DP. Metazoan microRNAs. Cell. 2018;173(1):20–51.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. Interplay between SOX9 transcription factor and microRNAs in cancer. Int J Biol Macromol. 2021;183:681–694.
   PubMed Web of Science ®Google Scholar
• Paskeh MDA, Mirzaei S, Orouei S, et al. Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Int J Biol Macromol. 2021;191:727–737.
   PubMed Web of Science ®Google Scholar
• Liang ZZ, Guo C, Zou MM, et al. circRNA-miRNA-mRNA regulatory network in human lung cancer: an update. Cancer Cell Int. 2020;20:173.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Gholami MH, Hushmandi K, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Zarrabi A, Hashemi F, et al. Regulation of nuclear factor-KappaB (NF-kappaB) signaling pathway by non-coding RNAs in cancer: inhibiting or promoting carcinogenesis? Cancer Lett. 2021;509:63–80.
   PubMed Web of Science ®Google Scholar
• Bi R, Wei W, Lu Y, et al. High hsa_circ_0020123 expression indicates poor progression to non-small cell lung cancer by regulating the miR-495/HOXC9 axis. Aging (Albany NY). 2020;12(17):17343–17352.
   PubMedGoogle Scholar
• Wang L, Tang L, Ge T, et al. LncRNA DLGAP1-AS2 regulates miR-503/cyclin D1 to promote cell proliferation in non-small cell lung cancer. BMC Pulm Med. 2021;21(1):277.
   PubMed Web of Science ®Google Scholar
• Li K, Fan X, Yan Z, et al. Circ_0000745 strengthens the expression of CCND1 by functioning as miR-488 sponge and interacting with HuR binding protein to facilitate the development of oral squamous cell carcinoma. Cancer Cell Int. 2021;21(1):271.
   PubMed Web of Science ®Google Scholar
• Pang J, Ye L, Zhao D, et al. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. Cell Biol Int. 2020;44(12):2416–2426.
   PubMed Web of Science ®Google Scholar
• Li S, Zeng M, Yang L, et al. Hsa_circ_0008934 promotes the proliferation and migration of osteosarcoma cells by targeting miR-145-5p to enhance E2F3 expression. Int J Biochem Cell Biol. 2020;127:105826.
   PubMed Web of Science ®Google Scholar
• Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem. 1999;34:191–211.
   PubMed Web of Science ®Google Scholar
• Ma S, Kong S, Wang F, et al. CircRNAs: biogenesis, functions, and role in drug-resistant tumours. Mol Cancer. 2020;19(1):119.
   PubMed Web of Science ®Google Scholar
• Chen H, Li F, Xue Q. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement. Bioengineered. 2022;13(2):2828–2840.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhao L, Li Q, et al. Circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. Thorac Cancer. 2020;11(8):2196–2208.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang M, Zhang Y. Circ_0000079 decoys the RNA-binding protein FXR1 to interrupt formation of the FXR1/PRCKI complex and decline their mediated cell invasion and drug resistance in NSCLC. Cell Transplant. 2020;29:963689720961070.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhao R, Wang H, et al. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis. J Buon. 2021;26:1850–1861.
   PubMedGoogle Scholar
• Zou C, Rong F, Zeng Y, et al. Circ-SNAP47 (hsa_circ_0016760) and miR-625-5p are regulators of WEE1 in regulation of chemoresistance, growth and invasion of DDP-tolerant NSCLC cells via ceRNA pathway. Environ Toxicol. 2022;37(2):224–236.
   PubMed Web of Science ®Google Scholar
• Feng N, Guo Z, Wu X, et al. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Respir Res. 2021;22(1):248.
   PubMed Web of Science ®Google Scholar
• Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, et al. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. IJMS. 2021;22(16):8885.
   Google Scholar
• Sun B, Hu N, Cong D, et al. MicroRNA-25-3p promotes cisplatin resistance in non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route. Bioengineered. 2021;12(1):3219–3228.
   PubMed Web of Science ®Google Scholar
• Liu B, Wang R, Liu H. Mir-126-5p promotes cisplatin sensitivity of Non-Small-Cell lung cancer by inhibiting ADAM9. Biomed Res Int. 2021;2021:6622342.
   PubMed Web of Science ®Google Scholar
• Deng SH, Wu DM, Li L, et al. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Biochem Biophys Res Commun. 2021;549:54–60.
   PubMed Web of Science ®Google Scholar
• Li J, Song Y, Yu B, et al. TNFAIP2 promotes non-small cell lung cancer cells and targeted by miR-145-5p. DNA Cell Biol. 2020;39(7):1256–1263.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang P, Qu C, et al. Circular RNA circ_0000677 promotes cell proliferation by regulating microRNA-106b-5p/CCND1 in non-small cell lung cancer. Bioengineered. 2021;12(1):6229–6239.
   PubMed Web of Science ®Google Scholar
• Ju ZS, Sun B, Bao D, et al. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Eur Rev Med Pharmacol Sci. 2020;24(18):9465–9472.
   PubMed Web of Science ®Google Scholar
• Dori M, Bicciato S. Integration of bioinformatic predictions and experimental data to identify circRNA-miRNA associations. Genes (Basel. 2019;10(9):642.
   PubMed Web of Science ®Google Scholar